FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|March 22, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of March 22, 2022
Author(s)Sydney Jennings
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, March 22, 2022, at 3:47 PM, EDT:
44.5% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
According to the CDC as of today, March 22, 2022, at 3:47 PM, EDT:
• 65.4% of total US population
• 69.5% of US population aged ≥5 years
• 73.8% of US population aged ≥12 years
• 75.3% of US population aged ≥18 years
• 88.9% of US population aged ≥65 years
The 5 states/territories with the highest percentage of population fully vaccinated are:
1. Puerto Rico: 82%
2. Rhode Island: 81.3%
3. Vermont: 80.5%
4. Maine: 78.7%
5. Connecticut: 78.2%
2. Rhode Island: 81.3%
3. Vermont: 80.5%
4. Maine: 78.7%
5. Connecticut: 78.2%
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, March 22, 2022 at 3:20 PM, EDT, there have been:
• 79 797 106 confirmed cases and
• 973 196 deaths
• 973 196 deaths
The 5 states with the highest total confirmed cases are:
1. California: 9 075 644
2. Texas: 6 698 309
3. Florida: 5 868 263
4. New York: 4 965 351
5. Illinois: 3 057 078
2. Texas: 6 698 309
3. Florida: 5 868 263
4. New York: 4 965 351
5. Illinois: 3 057 078
Deaths: California has the highest number of deaths due to COVID-19 with 88 233 reported fatalities, followed by Texas with 86 988 and Florida with 72 767.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 473 083 504 confirmed cases, 6 097 351 deaths, and 10 818 047 370 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
Advertisement
Advertisement
Trending on Patient Care Online
1
Switch to Oral Semaglutide Linked to 4.1% Weight Loss at 3 Months in New Study
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
5